Compositions and products for infectious or inflammatory diseases or conditions
Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.
1. A composition, comprising:
about 0.01 mg/mL to about 20 mg/mL of N-acetylneuraminic acid;
about 0.01 mg/mL to about 20 mg/mL of N-acetylneuraminic acid methyl ester; and
about ¼ to about ¾ of the manufacturer's recommended dose of Tamiflu for the treatment of influenza; or
about ¼ to about ¾ of the manufacturer's recommended dose of Enrofloxacin for the treatment of rotavirus infection or diarrhea; or
about ¼ to about ¾ of the manufacturer's recommended dose of Tilmicosin for the treatment of respiratory infections, respiratory syndrome, asthma, or other respiratory disorders; or
about ¼ to about ¾ of the manufacturer's recommended dose of Cephradine for the treatment of diarrhea, dehydration, or gastroenteritis; or
about ¼ to about ¾ of the manufacturer's recommended dose of Tulathromycin for the treatment of respiratory infections or disorders.
2. The composition of claim 1 , wherein the composition is a nutritional supplement, a food, a feed, a medicated food additive, a medicated feed additive, a therapeutic composition, a rehydration salt, or a rehydration solution.
3. The composition of claim 1 , wherein the composition is used to treat infectious and inflammatory diseases caused by viral or bacterial infections, gastroenteritis, nutritional problems, food intolerances, inflammation, allergy, gastrointestinal and respiratory diseases or conditions, cancers or autoimmune diseases.
4. The composition of claim 1 , wherein the composition is in the form of a tablet, capsule, pill, powder, granule, elixir, tincture, solution, suspension, syrup, emulsion, nasal drop or spray, an injectable, an infusion, or a form conjugated to a nano-particle.
5. The composition of claim 1 , wherein the composition comprises about 2 mg/mL to about 20 mg/mL N-acetylneuraminic acid.
6. The composition of claim 1 , wherein the composition further comprises N-acetylglucosamine.
7. The composition of claim 1 , wherein the composition comprises about 2 mg/mL to about 20 mg/mL of N-acetylneuraminic acid methyl ester.
8. The composition of claim 1 , wherein the composition comprises about 2 mg/g to about 20 mg/g of the N-acetylneuraminic acid.
9. The composition of claim 8 , wherein the composition comprises about 2 mg/g to about 20 mg/g of N-acetylneuraminic acid methyl ester.
10. The composition of claim 1 , wherein the composition comprises about 2 mg/g to about 20 mg/g of N-acetylneuraminic acid methyl ester.
11. A method of making a composition of claim 1 , the method comprising:
adding N-acetylneuraminic acid and N-acetylneuraminic acid methyl ester to a composition comprising an antibiotic, wherein the concentration of the N-acetylneuraminic acid in the composition is between about 0.1 mg/mL to about 20 mg/mL and the concentration of the N-acetylneuraminic acid methyl ester in the composition is between about 0.1 mg/mL to about 20 mg/mL, and wherein the concentration of Tamiflu in the composition is about ¼ to about ¾ of the manufacturer's recommended dose for the treatment of influenza, or the concentration of the Enrofloxacin in the composition is about ¼ to about ¾ of the manufacturer's recommended dose for the treatment of rotavirus infection or diarrhea, or the concentration of the Tilmicosin in the composition is about ¼ to about ¾ of the manufacturer's recommended dose for the treatment of respiratory infections, respiratory syndrome, asthma, or other respiratory disorders, or the concentration of the Cephradine in the composition is about ¼ to about ¾ of the manufacturer's recommended dose for the treatment of diarrhea, dehydration, or gastroenteritis, or the concentration of the Tulathromycin in the composition is about ¼ to about ¾ of the manufacturer's recommended dose for the treatment of respiratory infections or disorders,
wherein the composition is a nutritional supplement, or a food, or a feed, or a medicated food additive, or a medicated feed additive, or a therapeutic composition, or a rehydration salt or a rehydration solution.